跳转到主要内容

Choline kinase α interacts with epidermal growth factor receptor to activate the mitogen-activated protein kinase pathway and contributes to glioma tumorigenesis

中华医学杂志(英文版) 2026 年第 139 卷第 5 期 741-753 页

DOI:10.1097/CM9.0000000000003977

8

作者人数

0

被引次数

来源:Crossref,截至 2026-10-20

作者

  1. 1
    Yourui Zou 第一作者
  2. 2
    Xiao Wu
  3. 3
    Yang Liu
  4. 4
    Yang Zhao
  5. 5
    Haibo Liu
  6. 6
    Jin Feng
  7. 7
    Peng Gao
  8. 8
    Hui Ma

参考文献 共 41 条

  1. 1 Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  2. 2 Cancer statistics, 2023
  3. 3 Management of glioblastoma: State of the art and future directions
  4. 4 Primary brain tumours in adults 10.1016/s0140-6736(23)01054-1
  5. 5 Diffuse glioma heterogeneity and its therapeutic implications 10.1158/2159-8290.cd-20-1474
  6. 6 Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions 10.1016/j.jconrel.2022.09.065
  7. 7 Immunotherapy for malignant glioma: Current status and future directions 10.1016/j.tips.2019.12.003
  8. 8 Molecular structure and differential function of choline kinases CHKα and CHKβ in musculoskeletal system and cancer 10.1016/j.cytogfr.2016.10.002
  9. 9 Choline kinases: Enzymatic activity, involvement in cancer and other diseases, inhibitors 10.1002/ijc.35286
  10. 10 Exploiting altered patterns of choline kinase-alpha expression on human prostate tissue to prognosticate prostate cancer 10.1136/jclinpath-2015-202859
  11. 11 Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: A retrospective study 10.1016/s1470-2045(07)70279-6
  12. 12 Choline kinase alpha and hexokinase-2 protein expression in hepatocellular carcinoma: Association with survival 10.1371/journal.pone.0046591
  13. 13 Choline kinase alpha 2 acts as a protein kinase to promote lipolysis of lipid droplets 10.1016/j.molcel.2021.05.005
  14. 14 Recent advances in the design of choline kinase α inhibitors and the molecular basis of their inhibition 10.1002/med.21746
  15. 15 Small molecule EGFR inhibitors as anti-cancer agents: Discovery, mechanisms of action, and opportunities 10.3390/ijms24032651
  16. 16 EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance 10.3390/cancers13112748
  17. 17 MAPK signaling pathway-based glioma subtypes, machine-learning risk model, and key hub proteins identification 10.1038/s41598-023-45774-0
  18. 18 The functional role of p38 MAPK pathway in malignant brain tumors 10.3389/fphar.2022.975197
  19. 19 Chinese glioma genome atlas (CGGA): A comprehensive resource with functional genomic data from chinese glioma patients 10.1016/j.gpb.2020.10.005
  20. 20 UALCAN: An update to the integrated cancer data analysis platform 10.1016/j.neo.2022.01.001
  21. 21 Choline kinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target 10.1093/jnci/djv371
  22. 22 Choline kinase alpha regulates autophagy-associated exosome release to promote glioma cell progression 10.1016/j.bbrc.2024.151269
  23. 23 Knockdown of choline kinase α (CHKA) inhibits the proliferation, invasion and migration of human U87MG glioma cells (in Chinese)
  24. 24 In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells 10.1371/journal.pone.0180263
  25. 25 Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells 10.18632/oncotarget.12337
  26. 26 Can EGFR be a therapeutic target in breast cancer 10.1016/j.bbcan.2022.188789
  27. 27 Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways 10.1186/s12943-017-0621-z
  28. 28 Dual EGFR-VEGF pathway inhibition: A promising strategy for patients with EGFR-mutant NSCLC 10.1016/j.jtho.2020.10.006
  29. 29 An anti-EGFR antibody-drug radioconjugate labeled with actinium-225 elicits durable antitumor responses in KRAS- and BRAF-mutant colorectal cancer 10.1158/0008-5472.can-24-2266
  30. 30 DRD1 suppresses cell proliferation and reduces EGFR activation and PD-L1 expression in NSCLC 10.1002/1878-0261.13608
  31. 31 Prognostic and predictive biomarkers in gliomas 10.3390/ijms221910373
  32. 32 IGF2BP3-EGFR-AKT axis promotes breast cancer MDA-MB-231 cell growth 10.1016/j.bbamcr.2023.119542
  33. 33 VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer 10.1016/j.ebiom.2023.104451
  34. 34 MicroRNA-137 regulates hypoxia-mediated migration and epithelial-mesenchymal transition in prostate cancer by targeting LGR4 via the EGFR/ERK signaling pathway 10.3892/ijo.2020.5064
  35. 35 Updated insights on EGFR signaling pathways in glioma 10.3390/ijms22020587
  36. 36 Functional interactions between Choline kinase α, epidermal growth factor receptor and c-Src in breast cancer cell proliferation 10.1038/onc.2011.332
  37. 37 A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation
  38. 38 Overexpression of CHKA contributes to tumor progression and metastasis and predicts poor prognosis in colorectal carcinoma 10.18632/oncotarget.11433
  39. 39 Choline kinase α mediates interactions between the epidermal growth factor receptor and mechanistic target of rapamycin complex 2 in hepatocellular carcinoma cells to promote drug resistance and xenograft tumor progression 10.1053/j.gastro.2016.12.033
  40. 40 A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling 10.1038/onc.2011.51
  41. 41 Choline kinase alpha promoted glioma development by activating PI3K/AKT signaling pathway

数据来源

论文信息:
中华医学期刊网、Crossref
作者名单:
Crossref
被引次数:
Crossref,截至 2026-10-20
参考文献:
Crossref

论文的著作权归作者与出版方所有,本站只整理公开的题录信息并附原文链接,不构成任何医疗建议。